CombiGene - About the company
CombiGene is a series B company based in Lund (Sweden), founded in 1999. It operates as a Provider of gene therapy for the treatment of rare diseases. CombiGene has raised an undisclosed amount in funding from Spark Therapeutics. The company has 583 active competitors, including 208 funded and 140 that have exited. Its top competitors include companies like Alnylam, Spark Therapeutics and Strand Therapeutics.
Company Details
Provider of gene therapy for the treatment of rare diseases. It offers a peptide treatment and a gene therapy treatment for severe chronic pain. It also provide AAV-based gene therapy with a combination of neuropeptide Y for drug-resistant focal epilepsy treatment.
- Website
- combigene.com
- Social
- Email ID
- *****@combigene.com
Key Metrics
Founded Year
1999
Location
Lund, Sweden
Stage
Series B
Latest Funding Round
Investors
Ranked
314th among 583 active competitors
Employee Count
4 as on May 31, 2026
Sign up to download CombiGene's company profile
CombiGene's funding and investors
CombiGene has raised funding over 3 rounds. Its first funding round was on Aug 01, 2018. Its latest funding round was a Series B round on Oct 12, 2021 for $*****. 1 investor participated in its latest round. CombiGene has 3 institutional investors.
Here is the list of recent funding rounds of CombiGene:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Oct 12, 2021 | 4417413 | Series B | 3675371 | 7133366 | 3454466 | 5378036 |
Jul 31, 2021 | 7362459 | Grant (prize money) | 8999719 | 1030831 | 7348367 | |
Aug 01, 2018 | 4999666 | Grant (prize money) | 7090459 | 7652266 | 8508472 |
Access funding benchmarks and valuations. Sign up today!View details of CombiGene's funding rounds and investors
CombiGene's founders and board of directors
Founder? Claim ProfileCombiGene's employee count trend
CombiGene has 4 employees as of May 26. Here is CombiGene's employee count trend over the years:
Uncover CombiGene's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
CombiGene's Competitors and alternates
Top competitors of CombiGene include Alnylam, Spark Therapeutics and Strand Therapeutics. Here is the list of Top 10 competitors of CombiGene, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Alnylam 2002, Cambridge (United States), Public | Developer of RNA interference-based therapeutics for multiple disorders | $17M | 79/100 | |
2nd | Spark Therapeutics 2013, Philadelphia (United States), Acquired | Developer of gene therapy for rare diseases | $82.8M | 73/100 | |
3rd |  Strand Therapeutics 2017, Cambridge (United States), Series B | Provider of platform to deliver mRNA therapeutics for multi functional treatments | $256M | 70/100 | |
4th |  Forge Biologics 2020, Columbus (United States), Acquired | Developer of gene therapeutic solutions for treating multiple diseases | $330M | 70/100 | |
5th |  Insitro 2018, San Francisco (United States), Series C | Developer of machine learning platform for drug discovery and development | $643M | 70/100 | |
6th | _1560516450043.png?devicePixelRatio=2&height=30&width=30){kind=logo} Passage Bio 2017, Philadelphia (United States), Public | Developer of gene therapies for CNS rare diseases | $226M | 69/100 | |
7th | Ultragenyx 2010, Novato (United States), Acquired | Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases | $135M | 69/100 | |
8th |  Generation Bio 2016, Cambridge (United States), Acquired | Developer of gene therapies for rare liver and eye diseases | $236M | 69/100 | |
9th | ElevateBio 2018, Cambridge (United States), Series D | Provider of transnational research for portfolio of cell and gene therapy | $1.25B | 68/100 | |
10th | Krystal Biotech 2015, Pittsburgh (United States), Public | Developer of genetic medicines to treat rare diseases | $11.3M | 67/100 | |
314th | Provider of gene therapy for the treatment of rare diseases | - | 34/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on CombiGene's competitors? Click here to see the top ones
CombiGene's Investments and acquisitions
CombiGene has made no investments or acquisitions yet.
News related to CombiGene
Filter this list•
•
CombiGene positive to new license agreement for CG01Cision•Jun 26, 2024•Spark Therapeutics, CombiGene
•
Entrada Therapeutics announces $100M registered direct offeringSeeking Alpha•Jun 24, 2024•Entrada Therapeutics, NeuroBo Pharmaceuticals, Vico, Takeda and 3 others
•
•
CombiGene’s CEO comments on the patent approvals in Australia and IndiaCision•Mar 20, 2024•CombiGene
•
•
Strategic co -ownership of the biotech company Combigene ABGlobeNewswire•Feb 21, 2024•CombiGene, Orphazyme ApS
•
CombiGene has chosen CRO for the pain projectCision•Nov 01, 2023•Charles River Laboratories, ZYNEYRO, CombiGene
•
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about CombiGene
Explore our recently published companies
- Shop Wafi - Jeddah based, 2015 founded, Deadpooled company
- Bixabotanical - Mumbai based, 2015 founded, Unfunded company
- Benhurconstruction - Unfunded company
- Saalfo Tech - Mysuru based, 2016 founded, Unfunded company
- Tolia - Thane based, 1979 founded, Unfunded company
- Uvtcpl - Mumbai based, 2023 founded, Unfunded company
